GULF PHARMACEUTICAL INDUSTRIES |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.998 AED | +0.30% |
|
+7.43% | +29.78% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Most analysts recommend that the stock should be sold or reduced.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +29.78% | 313M | C+ | ||
| +5.48% | 69.91B | A | ||
| +12.55% | 9.24B | A- | ||
| -13.75% | 5.05B | A- | ||
| +42.38% | 4.47B | - | ||
| +4.51% | 3.92B | B- | ||
| -19.05% | 2.41B | C- | ||
| -28.72% | 2.23B | - | ||
| +11.13% | 2.02B | - | - | |
| +6.53% | 1.66B | D+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
- Stock Market
- Equities
- JULPHAR Stock
- Ratings Gulf Pharmaceutical Industries
